This site uses cookies to improve user experience by collecting data. By continuing to use this website, you agree to the use of cookies and similar technologies as described in our 隱私政策.
確認

抗體細胞連結技術(ACC)

結合抗體與細胞療法對抗癌症
育世博正在開發強效、現成型、能標靶癌症的細胞療法,以釋放免疫系統對抗實體腫瘤及血液癌症。

抗體細胞連結技術(ACC)承襲Carolyn Bertozzi教授發展生物正交化學的前瞻研究,將點擊化學發展至可作用在活體生物上。Carolyn Bertozzi教授於2022年獲得諾貝爾化學獎。抗體細胞連結技術採用活細胞相容性化學,將任何標靶腫瘤的抗體連結至人類免疫細胞表面。透過開啟多種受體之訊息傳遞路徑,大幅增強oNK細胞以及γδ2 T細胞去辨識及接觸到腫瘤的能力,以此強效、全新的方法來開發細胞療法。這種潛力使得ACC-γδ2 T細胞及oNK細胞療法能夠去克服以往細胞療法無法有效標靶實體腫瘤的挑戰。
 
未命名-1
PLAY VIDEO
採用ACC法
Highly Versatile and Broadly Applicable

Highly Versatile and Broadly Applicable

In addition to the benefits of potency conferred by ACC, its simplicity and modular “plug and play” nature could make cell therapies more accessible to patients and allows for the expansion into other indications beyond oncology and other immune cells.
Highly Affinity and Selectivity

Highly Affinity and Selectivity

The antibody-cell conjugation(ACC) can be divided into three elements. The click chemistry is involved in the conjugation process that clicks antibodies to the live cells. And the aptamer we use in ACC is functional as a T cell engager, one arm engages with T cell and the other arm can selectively grab tumor cell which subsequently enhances potency through immune activation receptors activating NFAT signaling pathway. The covalent bonding of aptamer sustains the high affinity of antibody-conjugated effector cells toward the tumor cells.
In the Clinic: ACC candidate for solid tumors and hematological malignancies

In the Clinic: ACC candidate for solid tumors and hematological malignancies

Acepodia’s lead clinical candidates are ACE1831(CD20-targeting ACC- gamma delta2 (γδ2) T cell therapy) and ACE1702 (HER2-targeting ACC-oNK cell therapy). ACE1702 is developed for the treatment of HER2-expressing solid tumors. ACE1831 is developed for the treatment of relapsed / refractory non-Hodgkin’s lymphoma.

Potent, Off-the-Shelf Cell Lines as the Chassis for our ACC Technology

In order to develop the most effective immunotherapies possible, Acepodia equips its ACC technology to both of its proprietary gamma delta2 (γδ2) T cells and off-the-shelf NK (oNK) cells which are allogeneic, and specially selected for enhanced tumor engagement. ACC allows for any antibody, new or existing, to be conjugated to the stimulatory surface receptors of these immune cells to yield the additive effect of superior tumor targeting to our already potent and off-the-shelf biologic drug payloads.

PIPELINE

PROMISING PIPELINE OF CELL THERAPIES

ACC-γδ2 T

開發中產品
早期探索
前臨床
第I期
第II期
ACE1831
CD20標靶、ACC-γδ2 T細胞療法
Phase I ​
ACE2016
抗EGFR、ACC-γδ2 T細胞療法
Preclinical ​
ACE1708
抗PD-L1、ACC-γδ2 T細胞療法
Discovery ​

ACC-oNK

開發中產品
早期探索
前臨床
第I期
第II期
ACE1702
抗HER2、ACC-oNK細胞療法
Phase I ​
We have collaborated with biopharmaceutical partners and academic institutes worldwide.